Worthy Endeavor: Inovio Surges as First DNA Medicine Wins FDA Approval
Inovio’s first FDA approval sends shares sharply higher, but the launch of Voceryq now brings a fresh test: generating commercial revenue while funding further studies and extending a limited cash runway.
NASDAQ: INO — Inovio Pharmaceuticals has reached its biggest regulatory milestone. The FDA granted accelerated approval to Voceryq on October 30, giving the company its first commercial product and opening a new chapter for its DNA medicine platform.
Investors responded with a dramatic rally. Shares closed at $1.89 on November 2, up approximately 214%, with roughly 222 million shares changing hands. The move reflects renewed expectations for the business, although the challenges of launching a treatment and financing operations remain.
Previously known as INO-3107, Voceryq is approved to reduce the frequency of surgical papilloma removals in adults with recurrent respiratory papillomatosis, or RRP. The disease causes recurring growths in the respiratory tract that can require repeated surgery. The treatment uses plasmid DNA and Inovio’s CELLECTRA delivery device to stimulate an immune response against the HPV types responsible for the disease. Inovio describes it as the first FDA-approved DNA medicine.
The supporting study enrolled 32 adults. Among the 26 patients included in the efficacy population, seven required no surgery during the 12 months following treatment. Those patients had previously undergone at least three surgeries in the preceding year. The findings supported accelerated approval, but further evidence is needed to verify clinical benefit.
Inovio expects Voceryq to become available for ordering and shipping approximately 60 days after approval, followed by full commercial deployment in the first quarter of 2027. It has engaged Syneos Health to support its medical and commercial field teams. The company must also submit a draft confirmatory study protocol by the end of 2026, with final alignment expected by mid-2027.
Funding remains a central concern. Inovio held $36.7 million in cash, cash equivalents and short-term investments at June 30. Including approximately $18.3 million raised in July, management previously projected enough funding to support operations into late first quarter 2027. That timetable leaves limited room between the planned launch and the anticipated end of its cash runway.
Additional financing could dilute shareholders, while pricing, insurance coverage and physician adoption will help determine how quickly approval translates into revenue.
Investor Take: Voceryq’s approval materially changes Inovio’s prospects, but commercial execution now becomes the key test. Early orders, reimbursement progress and financing terms will show whether the company can build a sustainable business around its first approved product.
What we’re watching: Initial shipments, early sales, the confirmatory study design and an updated funding plan.
This is editorial research, not an investment recommendation.
Comments